Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.

about

Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.

Item

http://www.wikidata.org/entity/Q36074388

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

1996年學術文章

@zh

1996年學術文章

@zh-hant

name

Moving the Frontiers of Cancer ...... the Scope of Drug Development.

@ast

Moving the Frontiers of Cancer ...... the Scope of Drug Development.

@en

type

Item

label

Moving the Frontiers of Cancer ...... the Scope of Drug Development.

@ast

Moving the Frontiers of Cancer ...... the Scope of Drug Development.

@en

prefLabel

Moving the Frontiers of Cancer ...... the Scope of Drug Development.

@ast

Moving the Frontiers of Cancer ...... the Scope of Drug Development.

@en

P1476

Moving the Frontiers of Cancer ...... the Scope of Drug Development.

@en

P2093

J Verweij

http://www.w3.org/2001/XMLSchema#string

M J De Jonge

http://www.w3.org/2001/XMLSchema#string

P2860

The molecular heterogeneity of protein kinase C and its implications for cellular regulation

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

Preclinical and phase I trials of topoisomerase I inhibitors.

cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment.

Cytoskeleton-disrupting drugs enhance effect of growth factors and hormones on initiation of DNA synthesis.

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.

Mechanism of action of taxol.

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

P304

183-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10245332.1996.11746304

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

1996-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27406612

http://www.w3.org/2001/XMLSchema#string